TABLE 2.
Description of use of the 5 most frequent primary APs (plus cyamemazine).
| Risperidone (n = 2,661) |
Cyamemazine (n = 2,581) |
Olanzapine (n = 1,636) |
Tiapride (n = 1,213) |
Haloperidol (n = 1,036) |
Aripiprazole (n = 896) |
|||||||
| Mean (SD) | Median (Q1–Q3) |
Mean (SD) | Median (Q1–Q3) |
Mean (SD) | Median (Q1–Q3) |
Mean (SD) | Median (Q1–Q3) |
Mean (SD) | Median (Q1–Q3) |
Mean (SD) | Median (Q1–Q3) |
|
| Age at inclusion | 61.1 (22.2) | 62.0 (42−82.0) | 52.5 (16.3) | 51.0 (41.0−62.0) | 49.0 (16.9) | 47.0 (36.0−59.0) | 68.6 (18.8) | 74.0 (54.0−84.0) | 61.5 (19.3) | 60.0 (46.0−79.0) | 44.2 (15.0) | 43.0 (33.0−53.0) |
| Mean time between 2 dispensings, over the first 12 months of follow-up (in days) | 36.1 (12.6) | 32.6 (28.0−40.4) | 34.1 (11.8) | 31.5 (27.5−38.3) | 30.8 (9.6) | 28.6 (26.2−32.9) | 34.0 (10.9) | 31.5 (28.0−37.3) | 35.0 (12.0) | 31.6 (28.3−38.1) | 31.8 (9.5) | 29.8 (26.9−34.5) |
| Number of dispensed units, over the first 12 months of follow-up | 11.7 (7.4) | 10.0 (7.0 −14.0) | 14.8 (12.0) | 12.0 (8.0−18.0) | 13.4 (7.7) | 13.0 (8.0−16.0) | 20.2 (15.1) | 16.0 (9.0−27.0) | 19.1 (20.2) | 13.0 (8.0−23.0) | 11.0 (5.6) | 11.0 (7.0−13.0) |
| Time on treatment (in months) | 42.5 (41.2) | 27.6 (11.5−60.8) | 48.8 (44.9) | 31.5 (11.0−78.2) | 51.8 (49.0) | 30.3 (10.7−86.3) | 30.7 (33.2) | 18.5 (7.1−42.6) | 61.1 (52.3) | 40.8 (13.8−115.4) | 41.3 (41.4) | 25.0 (8.3−61.8) |